In today’s crowded cannabis landscape, where “premium” is often used as a buzzword, The Medocann Group is setting a higher bar. Founded on nearly a century of family farming heritage and powered by state-of-the-art biotechnology, the Israeli company is redefining what premium truly means: consistency, purity, and precision at every stage of cultivation.
As part of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub we speak with Asaf Sella, Co-Founder and CEO, and Narkis Tessler, Chief of Strategy and Business Development, about Medocann’s philosophy, the technology behind their SMART indoor facility, and how they’re building long-term partnerships to take their craft cannabis to the global stage.
From pesticide-free cultivation and small-batch craftsmanship to patient loyalty and strategic international expansion, the discussion explores how Medocann is combining legacy, science, and vision to shape the future of ultra-premium cannabis.
Farming Meets Precision Engineering
“We approach cultivation not as farming alone, but as precision-driven biotechnology,” explains Asaf Sella, Co-Founder and CEO of Medocann. “Our SMART indoor facility is designed to maintain total environmental control — light, humidity, airflow, nutrients — allowing us to cultivate with zero pesticides and zero compromise.”
Unlike traditional greenhouse or hybrid set-ups, Medocann’s closed-loop indoor system ensures uniformity across every batch, every time. The team leverages data analytics, advanced automation, and real-time plant monitoring to optimize for potency, terpene retention, and cleanliness. The result? Predictable excellence, backed by rigorous quality assurance protocols and built to EU-GMP standards.
Beyond “Premium” — A New Global Standard
Medocann’s products are anything but off-the-shelf. The company cultivates in small batches, hand-trims every flower, and slow-cures each harvest to protect the delicate trichomes holding the cannabinoid and terpene profile of each cultivar. This care is reflected in its two signature lines: SEVEN, a therapeutic-grade collection trusted by Israeli patients and clinicians, and SOLO, an ultra-premium craft collection for cannabis connoisseurs.
“There’s a lot of talk about premium in this space, but for us, it’s a discipline,” says Sella. “Every decision — from phenohunting to post-harvest handling — is made to serve the integrity of the plant and the experience of the consumer.”
Strategic Global Expansion with Select Partners
With a mature domestic footprint in Israel — one of the most regulated and quality-driven cannabis markets globally — Medocann is now actively expanding its international presence.
“Our focus is on long-term partnerships with top-tier distributors who recognise the value of consistency, differentiation, and trust,” says Narkis Tessler, Chief of Strategy and Business Development. “We’re not looking to be just another supplier — we’re seeking partners who are committed to building long-term brand equity in the ultra-premium cannabis space.”
Known for their consistency and efficacy, Medocann’s SEVEN products quickly earn patient loyalty — driving repeat demand and helping partners build a strong, premium presence in their markets.
A Future Built on Integrity, Innovation, and Trust
As regulatory frameworks evolve and consumer expectations sharpen, Medocann believes the cannabis industry is entering its quality-first era.
“We see cannabis moving from commodity to connoisseurship,” says Tessler. “The future belongs to companies that can consistently deliver safety, efficacy, and elevated experiences — not just once, but every single time.”
With its SMART indoor facility, pesticide-free commitment, and a growing international footprint, The Medocann Group is ready to meet that future — and help shape it.
Interested in partnering with Medocann? Visit www.medocann.com or contact us (info@medocann.com) to explore how we can bring ultra-premium craft cannabis to your market — together.
Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.
Home / Cultivating Precision: Medocann’s Vision for Ultra-Premium Craft Cannabis on the Global Stage
Cultivating Precision: Medocann’s Vision for Ultra-Premium Craft Cannabis on the Global Stage
In today’s crowded cannabis landscape, where “premium” is often used as a buzzword, The Medocann Group is setting a higher bar. Founded on nearly a century of family farming heritage and powered by state-of-the-art biotechnology, the Israeli company is redefining what premium truly means: consistency, purity, and precision at every stage of cultivation.
As part of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub we speak with Asaf Sella, Co-Founder and CEO, and Narkis Tessler, Chief of Strategy and Business Development, about Medocann’s philosophy, the technology behind their SMART indoor facility, and how they’re building long-term partnerships to take their craft cannabis to the global stage.
From pesticide-free cultivation and small-batch craftsmanship to patient loyalty and strategic international expansion, the discussion explores how Medocann is combining legacy, science, and vision to shape the future of ultra-premium cannabis.
Farming Meets Precision Engineering
“We approach cultivation not as farming alone, but as precision-driven biotechnology,” explains Asaf Sella, Co-Founder and CEO of Medocann. “Our SMART indoor facility is designed to maintain total environmental control — light, humidity, airflow, nutrients — allowing us to cultivate with zero pesticides and zero compromise.”
Unlike traditional greenhouse or hybrid set-ups, Medocann’s closed-loop indoor system ensures uniformity across every batch, every time. The team leverages data analytics, advanced automation, and real-time plant monitoring to optimize for potency, terpene retention, and cleanliness. The result? Predictable excellence, backed by rigorous quality assurance protocols and built to EU-GMP standards.
Beyond “Premium” — A New Global Standard
Medocann’s products are anything but off-the-shelf. The company cultivates in small batches, hand-trims every flower, and slow-cures each harvest to protect the delicate trichomes holding the cannabinoid and terpene profile of each cultivar. This care is reflected in its two signature lines: SEVEN, a therapeutic-grade collection trusted by Israeli patients and clinicians, and SOLO, an ultra-premium craft collection for cannabis connoisseurs.
“There’s a lot of talk about premium in this space, but for us, it’s a discipline,” says Sella. “Every decision — from phenohunting to post-harvest handling — is made to serve the integrity of the plant and the experience of the consumer.”
Strategic Global Expansion with Select Partners
With a mature domestic footprint in Israel — one of the most regulated and quality-driven cannabis markets globally — Medocann is now actively expanding its international presence.
“Our focus is on long-term partnerships with top-tier distributors who recognise the value of consistency, differentiation, and trust,” says Narkis Tessler, Chief of Strategy and Business Development. “We’re not looking to be just another supplier — we’re seeking partners who are committed to building long-term brand equity in the ultra-premium cannabis space.”
Known for their consistency and efficacy, Medocann’s SEVEN products quickly earn patient loyalty — driving repeat demand and helping partners build a strong, premium presence in their markets.
A Future Built on Integrity, Innovation, and Trust
As regulatory frameworks evolve and consumer expectations sharpen, Medocann believes the cannabis industry is entering its quality-first era.
“We see cannabis moving from commodity to connoisseurship,” says Tessler. “The future belongs to companies that can consistently deliver safety, efficacy, and elevated experiences — not just once, but every single time.”
With its SMART indoor facility, pesticide-free commitment, and a growing international footprint, The Medocann Group is ready to meet that future — and help shape it.
Interested in partnering with Medocann? Visit www.medocann.com or contact us (info@medocann.com) to explore how we can bring ultra-premium craft cannabis to your market — together.
Ben Stevens
Other featured articles
Taima Growth Becomes Spain’s Fourth AEMPS-Licensed Medical Cannabis Cultivator
By
From Land to Brand: Why Cannabis’s Next Generation Is Going Asset-Light
By
Cannabis at an Inflexion Point: A Structural Repricing Ahead
By
Europe’s Medical Cannabis Market Has Grown Up, Now Its Supply Chain Needs To
By
Cannabis at an Inflexion Point: Why Capital Is Missing the Opportunity
By
Other featured Companies articles
Tilray Medical Brings Global Medical Cannabis Expertise to Cannabis Europa London 2026
By
Boxer Derek Chisora Reveals He Is Using Prescribed Medical Cannabis After 50 Fights to Combat Chronic Pain
By
Voices of Cannabis Europa: Philip Schetter, Joshua Cuby and Gabriel Newman, Cantourage
By
Voices of Cannabis Europa: Carmen Doran, Chair of the NZMCC, & Rawiri Manawatu, representative of Ngai Tahu
By
PGP Farmer Launches 30-Variety Dutch Trial to Set Dordogne Production Blueprint
By
Share Article
The Briefing / Newsletter
Insights
you don't want
to miss.
A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.
Related news
Taima Growth Becomes Spain’s Fourth AEMPS-Licensed Medical Cannabis Cultivator
By
From Land to Brand: Why Cannabis’s Next Generation Is Going Asset-Light
By
Cannabis at an Inflexion Point: A Structural Repricing Ahead
By
Europe’s Medical Cannabis Market Has Grown Up, Now Its Supply Chain Needs To
By
Cannabis at an Inflexion Point: Why Capital Is Missing the Opportunity
By
Tilray Medical Brings Global Medical Cannabis Expertise to Cannabis Europa London 2026
By
Boxer Derek Chisora Reveals He Is Using Prescribed Medical Cannabis After 50 Fights to Combat Chronic Pain
By
Voices of Cannabis Europa: Philip Schetter, Joshua Cuby and Gabriel Newman, Cantourage
By
From Green Success to BH Labs: Why the Next Cannabis Leaders Will Look More Like Technology Companies
By